key: cord-0794422-dgjbev9n authors: Heriyanto, Rivaldo Steven; Kurniawan, Andree; Wijovi, Felix; Halim, Devina Adella; Jodhinata, Claudia; Marcella, Elizabeth; Susanto, Billy; Wibowo, Johan; Indrawan, Michele; Heryadi, Nadia Khoirunnisa; Imanuelly, Michelle; Anurantha, Jonathan Juniard; Hariyanto, Timotius Ivan; Marcellin, Chintya; Sinaga, Terry Devita; Rizki, Saraswati Anindita; Sieto, Novia; Siregar, Jeremia Immanuel; Lugito, Nata Pratama Hardjo title: The role of COVID-19 survivor status and gender towards neutralizing antibody titers 1, 2, 3 months after sinovac vaccine administration on clinical year medical student in Indonesia date: 2021-10-12 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.10.009 sha: 5e457355ccb2d6d546aa850e843ccbb242de07a8 doc_id: 794422 cord_uid: dgjbev9n Background Sinovac was the first vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) used in Indonesia. However, data regarding the effects of certain variables such as clinical demographic on antibody levels in individuals vaccinated with Sinovac are scarce. We aimed to investigate the impact of gender and previous SARS-CoV-2 infection status on neutralizing antibody titers 1, 2, and 3 months after the administration of Sinovac vaccine. Method A cross-sectional study was conducted from February to May 2021. Data on neutralizing antibody levels, previous SARS-CoV-2 infection status, and gender were retrieved from the monthly quantitative serology evaluation database of Siloam Hospitals Lippo Village, Tangerang, Indonesia. The role of each variable was analyzed using the t-test or Mann-Whitney U test depending on data distribution. Result Data from 350 participants were collected for the study. Participants with a history of positive SARS-CoV-2 RT-PCR test had significantly higher neutralizing antibody titers in the first (144 U/mL, p = 0.036) and second month (144 U/mL, p = 0.005) after vaccination compared to those without history of positive RT-PCR test. Female participants also had significantly higher neutralizing antibody titers in the first, second, and third month (43 U/mL, 42 U/mL, and 39 U/mL, respectively; p = 0.001, 0.002, and 0.003, respectively) after vaccination compared to male. Conclusion COVID-19 survivor status and the female gender are associated with higher neutralizing antibody titers after Sinovac vaccine administration.  COVID-19 survivor role towards antibody titers post-Sinovac vaccination are unknown  Gender role towards antibody titers post-Sinovac vaccination are also unknown  COVID-19 survivor is associated with higher antibody titers during first two months  Females have higher antibody titers than males on all 3 months after vaccination  Male and female titers differ most in the 1 and 3 months after vaccination Abstract Background: Sinovac was the first vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) used in Indonesia. However, data regarding the effects of certain variables such as clinical demographic on antibody levels in individuals vaccinated with Sinovac are scarce. We aimed to investigate the impact of gender and previous SARS-CoV-2 infection status on neutralizing antibody titers 1, 2, and 3 months after the administration of Sinovac vaccine. Method: A cross-sectional study was conducted from February to May 2021. Data on neutralizing antibody levels, previous SARS-CoV-2 infection status, and gender were retrieved from the monthly quantitative serology evaluation database of Siloam Hospitals Lippo Village, Tangerang, Indonesia. The role of each variable was analyzed using the t-test or Mann-Whitney U test depending on data distribution. Result: Data from 350 participants were collected for the study. Participants with a history of positive SARS-CoV-2 RT-PCR test had significantly higher neutralizing antibody titers in the first (144 U/mL, p = 0.036) and second month (144 U/mL, p = 0.005) after vaccination compared to those without history of positive RT-PCR test. Female participants also had significantly higher neutralizing antibody titers in the first, second, and third month (43 U/mL, 42 U/mL, and 39 U/mL, respectively; p = 0.001, 0.002, and 0.003, respectively) after vaccination compared to male. Conclusion: COVID-19 survivor status and the female gender are associated with higher neutralizing antibody titers after Sinovac vaccine administration. Keywords: COVID-19, antibody titers, Sinovac vaccine, COVID-19 vaccine Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been actively circulating and causing disease for over a year (Jalkanen et al., 2021) . In Indonesia, the first case of coronavirus disease 2019 (COVID-19) was confirmed on March 2, 2020, and the virus has spread rapidly since then, disrupting multiple aspects of life including healthcare, such as by hindering routine childhood immunizations due to limited health services (Fahriani et al., 2021) . With the increasing incidence of SARS-CoV-2 infection, a high prevalence of long COVID-19 and its consequences have also been reported (Fahriani et al., 2021; Yusuf et al., 2021) . Several treatment agents have also been investigated to manage COVID-19 patients and reducing its mortality burden. (Hariyanto et al., 2021a; Hariyanto et al., 2021b; Hariyanto et al., 2021c) . To alleviate the impact of SARS-CoV-2 in Indonesia, the government began a COVID-19 Vaccination Program on January 13, 2021, which was split into four phases (Amira, 2021). The first phase prioritized healthcare workers and the used vaccine was CoronaVac, a COVID-19 vaccine produced by the Sinovac Life Sciencies, Beijing, China. Various studies have been conducted on the safety and efficacy of the Sinovac vaccine (Tanriover et al., 2021; Zhang et al., 2021) . However, data regarding the effect of different variables, such as gender and COVID-19 survivor status, on the antibody titers induced by this vaccine are scarce, and no data were found regarding Indonesia. A previous study reported that men are at a higher risk of poor prognosis and severe COVID-19 outcomes, while previous SARS-CoV-2 infections have a protective effect against reinfection (Vahidy et al., 2021; Vitale et al., 2021) . Thus, this study aimed to investigate the effect of COVID-19 survivor status and gender on neutralizing antibody titers 1, 2, and 3 months after Sinovac vaccine administration. A cross-sectional study was conducted between February and May 2021. Clinicalyear students of the Faculty of Medicine at Pelita Harapan University who had undergone a quantitative serology test were selected by convenience sampling from the student database. Their data was then collected from the Siloam Hospitals Lippo Village database. All clinicalyear students of the Faculty of Medicine at Pelita Harapan University having data from an IgG serology test, specifically to S1 subunit (receptor binding domain) conducted via electrochemiluminescence immunoassay (ECLIA; measured in U/mL) and a recorded Data were gathered from a total of 350 participants on 1, 2, and 3 months after the administration of the Sinovac COVID-19 vaccine. Table 1 displays the participant characteristics. The median neutralizing antibody titer after vaccination was 40 (1-250) U/mL in the first month, 40 (0-250) U/mL in the second month, and 36 (0-1051) U/mL in the third month. Most participants were female (70%, 71%, and 66%, respectively) and the majority did not have history of SARS-CoV-2 infection (95%, 95%, and 98%, respectively). The Mann-Whitney U test of the relationship between COVID-19 survivor status and neutralizing antibody titers (Table 2 ) showed a significantly higher titer during the first and second months after vaccination in those with history of SARS-CoV-2 infection, compared to those without history of SARS-CoV-2 infection (144 U/mL vs 40 U/mL for the first month, 144 U/mL vs 40 U/mL for the second month), while no significant difference was seen in the third month. Analysis of the relationship between gender and neutralizing antibody titers (Table 3 ) yielded significantly higher titer in women every month compared to male (43 U/mL vs 29 U/mL for the first month, 42 U/mL vs 39 U/mL for the second month, and 39 U/mL vs 29 U/mL for the third month). Higher neutralizing antibody titers were seen in women and participants with a history of SARS-CoV-2 infection. Our study found that neutralizing antibody titers were 2-4 times higher in the first two months after vaccine administration in participants with a previous SARS-CoV-2 infection. These results are similar to those of a study assessing antibody responses in seropositive individuals after a single dose of the SARS-CoV-2 vaccine (Krammer et al., 2021) , which found that the antibody titers of vaccinees with preexisting immunity were higher than those of individuals without preexisting immunity after a single dose of Pfizer and Moderna vaccine. A study assessing SARS-CoV-2 antibody responses in individuals with past infection also reported that significantly lower neutralizing antibody titers were found in patients without a history of SARS-CoV-2 infection (Anichini et al., 2021) . We also found that female participants had significantly higher neutralizing antibody titers in all three months after vaccination, as stated in another study that compared SARS-CoV-2 IgG antibody levels in men and women and found that female patients generated higher antibody counts compared with male patients (Zeng et al., 2020) . However, the exact cause of this gender-based is not known. Our study was limited by the low number of participants with a history of this may explain why the analysis of COVID-19 survivor status in relation to neutralizing antibody titer in the third month after vaccination yielded an insignificant result despite having a similar difference in median values to the first two months between those with and without history of SARS-CoV-2 infection group. We were also unable to analyze other variables due to limited data availability in the database. Future studies should ensure a better distribution of study participants and the analysis of other variables. Despite these limitations, to our knowledge, this study is the first to compare neutralizing antibody titers across three months after COVID-19 vaccination and thus provides valuable information to determine which group should be prioritized for further vaccine shots or booster shots. SARS-CoV-2 Antibody Response in Persons with Past Natural Infection Disruption of childhood vaccination during the COVID-19 pandemic in Indonesia Persistence of long COVID symptoms in COVID-19 survivors worldwide and its potential pathogenesis -A systematic review and meta-analysis Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and metaanalysis Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy Global prevalence of prolonged gastrointestinal symptoms in COVID-19survivors and potential pathogenesis: A systematic review andmeta-analysis A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Ethical approval statement: This study has been ethically approved by The EthicsCommittee of Faculty of Medicine, Pelita Harapan University with ethics number 085/K-LKJ/ETIK/II/2021.